Antibiotic therapy for Helicobacter pylori in patients with early gastric cancer is associated with a 50% lower risk for subsequent disease, trial findings indicate.

The overall survival of patients with resectable gastric cancer who have received adequate preoperative chemotherapy and surgery does not differ according to whether or not they receive postoperative chemoradiotherapy, phase III trial data show.

Second-line pembrolizumab does not significantly improve survival compared with paclitaxel in patients with advanced gastric or gastroesophageal junction cancer positive for programmed cell death ligand 1 expression, KEYNOTE-061 data show.

Professor Eva Segelov (Monash University, Australia) outlines her talk at ESMO Asia 2017.

The PD-1 inhibitor pembrolizumab elicits durable responses and has a manageable adverse event profile in previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma, indicates the KEYNOTE-059 trial.

Professor Jae-Ho Cheong (Yonsei University College of Medicine, Korea)   outlines his talk at ESMO Asia 2017.

We hope that by sharing expert experience and perspectives, it can help navigate the complexities of gastric cancer care and provide you with knowledge that you will be able to seamlessly apply to your own clinical practice.

Professor Ian Chau (Royal Marsden Hospital, UK), symposium chair, introduces the symposium at ESMO Asia 2017.

Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate.

Adding olaparib to paclitaxel does not improve survival among Asian patients with advanced gastric cancer that has progressed during or after first-line therapy, show results of the phase III GOLD trial.

These findings follow earlier FLOT4-AIO results for curative resection, OS, and PFS in favor of FLOT chemotherapy that were presented at the ASCO 2017 meeting in Chicago, Illinois, USA, Salah-Eddin Al Batran (University Cancer Center Frankfurt, Germany) told delegates at ESMO 2017 Congress in Madrid, Spain.

The long-term use of proton pump inhibitors for gastric acid-related disorders is associated with an elevated risk for gastric cancer in individuals who have received treatment for Helicobacter pylori infection, a population-based study indicates.

The GATSBY trial finds no significant difference in outcomes between patients with advanced human epidermal growth factor receptor 2-positive gastric cancer given second-line trastuzumab emtansine and those given a taxane.